Authorised Therapeutic exploratory (Phase II) previously untreated metastatic or locally advanced esophagogastric cancer

Liposomal iRInotecan, Carboplatin or oXaliplatin in the first line treatment of esophagogastric cancer: a randomized phase 2 study (LyRICX)

EU CTIS ID: 2023-509287-26-00

What this study is testing

To compare the progression free survival(= PFS 1: time from start of study treatment, until the first moment of disease progression) and neurotoxity of first line treatment with F-Nal-IRI, CapCar and CapOx.

  • Therapeutic exploratory (Phase II)

A plain-language read of the study's public EU CTIS listing. The study team confirms the details.

Who can take part

You may be able to join if

  • Patients must provide written informed consent according to ICH/GCP, and national/local regulations prior to any screening procedures
  • If a female patient is of child-bearing potential, as evidenced by regular menstrual periods, she must have a negative pregnancy test (urine or serum; beta-human chorionic gonadotropin (β-hCG)) documented prior to the first administration of study drug. If sexually active, the patient must agree to use contraception considered adequate and appropriate by the Investigator during the period of administration of study drug and after the end of treatment as recommended.
  • Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial.
  • Male or female adult patients (≥ 18 years).
  • Patients with histologically confirmed diagnosis of metastatic or irresectable HER2 negative adenocarcinoma of the stomach or oesophagus; patients with HER2 positive disease are eligible when treatment with trastuzumab is contraindicated. If histology cannot be obtained, cytology is acceptable to prove metastatic disease.
  • Patients with metastatic or irresectable adenocarcinoma of the stomach or oesophagus not pre-treated with systemic therapy for irresectable or metastatic disease. Palliative radiotherapy on the primary tumor or a metastatic lesion is allowed if other untreated lesions eligible for evaluation are present.

You likely can't join if

  • Any prior anti-cancer chemotherapy, biologic or investigational therapy for metastatic or irresectable stomach or oesophageal cancer
  • Signs of interstitial lung disease (ILD) − Patient has any other concurrent severe and/or uncontrolled medical condition that would, in the investigator’s judgment contraindicate patient participation in the clinical study.
  • Use of other investigational drugs within 30 days of enrollment
  • Patient is enrolled in any other clinical protocol or investigational trial that will interfere with the primary endpoint.
  • Patients who in the investigators’ opinion may be unwilling, unable or unlikely to comply with requirements of the study protocol.
  • Current use or any use in last two weeks of strong CYP3A-enzyme, CYP2C8, and/or strong UGT1A inhibitors/inhibitors
See the full eligibility criteria
Who can join
  • Patients must provide written informed consent according to ICH/GCP, and national/local regulations prior to any screening procedures
  • If a female patient is of child-bearing potential, as evidenced by regular menstrual periods, she must have a negative pregnancy test (urine or serum; beta-human chorionic gonadotropin (β-hCG)) documented prior to the first administration of study drug. If sexually active, the patient must agree to use contraception considered adequate and appropriate by the Investigator during the period of administration of study drug and after the end of treatment as recommended.
  • Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial.
  • Male or female adult patients (≥ 18 years).
  • Patients with histologically confirmed diagnosis of metastatic or irresectable HER2 negative adenocarcinoma of the stomach or oesophagus; patients with HER2 positive disease are eligible when treatment with trastuzumab is contraindicated. If histology cannot be obtained, cytology is acceptable to prove metastatic disease.
  • Patients with metastatic or irresectable adenocarcinoma of the stomach or oesophagus not pre-treated with systemic therapy for irresectable or metastatic disease. Palliative radiotherapy on the primary tumor or a metastatic lesion is allowed if other untreated lesions eligible for evaluation are present.
  • Measurable disease as assessed by RECIST 1.1
  • ECOG (WHO) performance status 0-2
  • Patient has adequate bone marrow and organ function as defined by the following laboratory values: o Absolute Neutrophil Count (ANC) > 1.5 x 109 /L o Hemoglobin (Hgb) > 5.6 mmol/L o Platelets > 100 x 109 /L
  • Serum total bilirubin within ≤ 1.5 x ULN (upper limit of normal); or total bilirubin < 3.0 x ULN with direct bilirubin within normal range in patients with well documented Gilbert’s syndrome; biliary drainage is allowed for biliary obstruction
  • Serum creatinine < 1.5 x ULN or creatinine clearance >30 mL/min/1.73 m2 − Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5x ULN within normal range or < 5.0 x ULN if liver metastases are present
What rules you out
  • Any prior anti-cancer chemotherapy, biologic or investigational therapy for metastatic or irresectable stomach or oesophageal cancer
  • Signs of interstitial lung disease (ILD) − Patient has any other concurrent severe and/or uncontrolled medical condition that would, in the investigator’s judgment contraindicate patient participation in the clinical study.
  • Use of other investigational drugs within 30 days of enrollment
  • Patient is enrolled in any other clinical protocol or investigational trial that will interfere with the primary endpoint.
  • Patients who in the investigators’ opinion may be unwilling, unable or unlikely to comply with requirements of the study protocol.
  • Current use or any use in last two weeks of strong CYP3A-enzyme, CYP2C8, and/or strong UGT1A inhibitors/inhibitors
  • Breast feeding, known pregnancy, positive serum pregnancy test or unwillingness to use a reliable method of birth control, during therapy and for 3 months following the last dose of study treatment.
  • Treatment within 4 weeks with DPD inhibitors, including sorivudine or its chemically related analogues such as brivudine.
  • Pre-existing motor or sensory neurotoxicity greater than CTCAE grade 1.
  • Disease progression within six months after completion of (neo)adjuvant chemotherapy containing a fluoropyrimidine and/or platinum compound and/or irinotecan; progression on neoadjuvant or definitive chemoradiation with carboplatin AUC2 and paclitaxel 50 mg/m2 within this time frame is allowed.
  • − All target lesions in a radiation field without documented disease progression
  • Patient has known brain metastases, unless previously treated and well-controlled for at least 3 months (defined as clinically stable, no edema, no steroids and stable in 2 scans at least 4 weeks apart).
  • Past or current malignancy other than entry diagnosis interfering with prognosis of metastatic esophagogastric cancer.
  • Known uncontrollable hypersensitivity or contraindications to any of the components of liposomal irinotecan (Nal-IRI) other liposomal irinotecan formulations, irinotecan, fluoropyrimidines, leucovorin, oxaliplatin, carboplatin. Patients with previous dose reductions or delays are eligible.
  • Complete dihydropyrimidine dehydrogenase deficiency.
  • Patient has active, uncontrolled bacterial, viral or fungal infection(s) requiring systemic therapy.
  • Patient has known past or active infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C.

The study team makes the final eligibility decision.

Questions & answers

Do participants get paid in this trial?

This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.

How long does this study last?

The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.

Who can join this trial?

This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.

Explore other conditions

ObesityType 2 diabetesType 1 diabetesPrediabetesWeight lossMetabolic syndromeHigh cholesterolHigh triglyceridesHigh blood pressurePCOSHypothyroidismThyroid diseaseGoutFatty liver disease (NAFLD/NASH)Heart failureCoronary artery disease

BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.